Cargando…
Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the one hand, by using tumor-infiltrating lymphocytes (TILs) and, on the other hand, by engineering T cells to obtain anti-tumor specificities through the introduction of either engineered T cell receptors...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739809/ https://www.ncbi.nlm.nih.gov/pubmed/36498890 http://dx.doi.org/10.3390/ijms232314563 |